tukysahcp.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Disallow: /sitecore Sitemap: | ||
Meta Tags
| Title | TUKYSA® (tucatinib) tablets | Official HCP |
| Description | Important Safety TUKYSA® (tucatinib), a HER2-directed treatment option for patients with certain HER2-positive cancers. Read full Indication and Important Safety |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 4.16.2.178 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
tukysahcp.com Valuation
|
US$6,471,360
Last updated: 2023-04-29 19:53:35
tukysahcp.com has Semrush global rank of 1,635,561. tukysahcp.com has an estimated worth of US$ 6,471,360, based on its estimated Ads revenue. tukysahcp.com receives approximately 746,696 unique visitors each day. Its web server is located in United States, with IP address 4.16.2.178. According to SiteAdvisor, tukysahcp.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$6,471,360 |
| Daily Ads Revenue | US$5,974 |
| Monthly Ads Revenue | US$179,207 |
| Yearly Ads Revenue | US$2,150,483 |
| Daily Unique Visitors | 49,780 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| tukysahcp.com. | A | 14399 | IP: 4.16.2.178 |
| tukysahcp.com. | NS | 14400 | NS Record: dns1.cscdns.net. |
| tukysahcp.com. | NS | 14400 | NS Record: dns2.cscdns.net. |
| tukysahcp.com. | TXT | 14400 | TXT Record: google-site-verification=c64ah3R3K6i6z5Us7JNrZZ94ir1AuVf6rCZ5lOg_ans |
HtmlToTextCheckTime:2023-04-29 19:53:35
| For US Healthcare Providers Learn about TUKYSA in HER2+ metastatic breast cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. Enter site NEW INDICATION Learn about TUKYSA in RAS WT, HER2+ metastatic colorectal cancer TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory |
HTTP Headers
HTTP/1.0 302 Moved Temporarily Location: https://www.tukysahcp.com/ Server: BigIP Connection: Keep-Alive Content-Length: 0 HTTP/2 200 date: Fri, 22 Oct 2021 16:28:28 GMT content-type: text/html; charset=UTF-8 content-length: 47797 server: Apache last-modified: Tue, 14 Sep 2021 17:39:45 GMT etag: "bab5-5cbf8113b9a40" accept-ranges: bytes |
tukysahcp.com Whois Information
Domain Name: TUKYSAHCP.COM Registry Domain ID: 2456663504_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2021-03-21T20:47:07Z Creation Date: 2019-11-18T17:49:46Z Registry Expiry Date: 2023-11-18T17:49:46Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: DNS1.CSCDNS.NET Name Server: DNS2.CSCDNS.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-11T06:41:04Z <<< |